Welcome reception

Welcome and introductions
Saad Usmani 

Session 1: Defining high-risk multiple myeloma
Chairs: Lawrence Boise & Leif Bergsagel

• Plasma cell identity escape as hallmark of high risk myeloma: Francesco Maura
• Defining functional high risk myeloma: Moritz Binder
• A T-cell signature identifies patients with poor outcomes: Chng Wee Joo
• Ultra-high-risk MM – update from OPTIMUM: Martin Kaiser
• Defining a high-risk microenvironment: Faith Davies
• Genomic instability underlies high-risk multiple myeloma: Gareth Morgan

Panel discussion

Break

Session 2: Circulating and extramedullary disease
Chairs: Dory Abelman & Kylee Maclachlan

• Non-invasive bone marrow surrogates for high-risk multiple myeloma: Juan José Garcés
• Fragmentomic and genomic profiling of cell-free DNA to track tumor burden in multiple myeloma: Dory Abelman
• Uncovering of high-risk features of extra- and paramedullary disease by spatial profiling: Niels Weinhold
• Paramedullary/extramedullary myeloma dataset: Kylee Maclachlan
• Spatial and single-cell characterization of bone marrow and extramedullary disease in myeloma: Manoj Bhasin
• Transcriptional profile of EMD and PCL: Saurabh Zanwar
• Tackling extramedullary disease with immunotherapy: Darren Pan

Panel discussion

 

Lunch

Session 3: NSD2/MMSET disease subset         

Chairs: Marta Chesi & Doris Hansen

• Targeting NSD2 and NSD2-dependent biology in t(4;14) MM: Benjamin Barwick
• Apoptotic dependencies in t(4;14) myeloma: Lawrence Boise
• The crossroads of t(4;14) breakpoints, NSD2 isoforms and patient outcome: Jonathan Keats
• Preclinical and translational data on a novel NSD2 inhibitor: Erin Flynt

Panel discussion           

Session 4: When standard risk isn’t: identifying functional high-risk myeloma

Chairs: Gareth Morgan & Erin Meermeier

• Rethinking standard risk: biology of high-risk t(11;14) MM: Linda Baughn
• Identifying tumor-reactive T cells: toward immune-based risk stratification in myeloma: Simone Minnie
• When does the immune system lose control? Host immune fitness as a determinant of high-risk myeloma: Erin Meermeier
• Beyond the tumor: the role of chronic inflammation in MM progression: Marta Chesi
• Transcriptional profiling and functional high-risk: Martin Kaiser

Panel discussion

Break

 

Session 5: What we know about antigen loss

Chairs: Hearn Cho & Francesco Maura

• Mechanisms of BCMA and GPRC5D antigen escape: Holly Lee
• Detection and quantifying antigen loss – clinical implications of antigen loss: Ajay Nooka
• Myeloma cell “identity” and immunotherapy failure: Ross Firestone
• Beyond the antigen: immune determinants of response and resistance to CAR T cells and T cell engagers: Tarek Mouhieddine

Panel discussion

Session 6: New approaches for high risk – lab and clinic

Chairs: Hearn Cho & Doris Hansen

• BCMA targeting in vivo CART in the clinic: Simon Harrison
• Engineering strategies for in vivo CAR deliveries: Karlo Perica
• BMS 986453, a dual targeting BCMA x GPRC5D CAR-T for the treatment of RRMM: Doris Hansen
• Harnessing Ferroptosis for t(4;14) Multiple Myeloma Therapy: Mala Shanmugam
• Going to Great Lengths: Long Read Sequencing to Transform Myeloma Risk Stratification: Sarah Gooding

Panel discussion

Day 1 conclusions

Kylee Maclachlan

Faculty dinner

Welcome to Day 2
Kylee Maclachlan

Session 8: Designing studies in high-risk MM

Chairs: Saad Usmani & George Mulligan

• Overcoming “classical” HRMM by TCE-combinations: Currently available data and impact on study design: Marc Raab
• How can we do trials for newly diagnosed high risk myeloma: trial designs and challenges: Sham Mailankody
• Timing of immunotherapy in randomized trials for high-risk myeloma: Binod Dhakal
• MMRC Horizon Two – an adaptive platform trial for high risk newly diagnosed multiple myeloma: Hearn Cho

Panel discussion

Session 7: MAF/MAFB disease

Chairs: Francesco Maura & Leif Bergsagel

• Should dysregulation of all MAF transcription factors be considered equal?: Jonathan Keats
• Pathways to high risk disease: Gareth Morgan
• PDX models show the presence of convergent evolution high-risk subclones in patient samples: Brian Walker

Panel discussion

Break

Session 9: Treatment sequencing in high-risk MM

Chairs: Hamza Hassan & Faith Davies

• Early T-cell engaging therapy vs ASCT in high-risk NDMM and PCL: Shonali Midha
• Single versus multi-antigen targeting in high-risk MM: Tom Martin
• Using ‘n’ of 1 for hypothesis generation in high-risk MM: Saad Usmani
• Immunotherapeutic sequencing for newly diagnosed primary refractory high-risk myeloma: Ajay Nooka

Panel discussion

Session 10: The evolving role of MRD-guided treatment decisions

Chairs: Sham Mailankody & Tom Martin

• Reaching and sustaining MRD negativity in patients with high-risk multiple myeloma: Douglas Sborov
• MRD-guided and genomics-informed treatment adaptation in myeloma: Benjamin Diamond
• Novel MRD testing through telomere analysis: Sandra Mazzoni

Meeting conclusions and close

Saad Usmani

Lunch and adjourn